Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
Sana Biotechnology (SANA) had its "overweight" rating reaffirmed by Morgan Stanley.
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression [Yahoo! Finance]
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology (SANA) was downgraded by Zacks Research from "strong-buy" to "hold".